• Advanced ovarian cancer: what is the best treatment for initial diagnosis today?

    With PARP inhibitors, the prognosis for ovarian cancer has improved significantly. How should a newly diagnosed high-grade malignancy be treated?

  • Charité Mayo Conference: Fighting cancer in women for 27 years

    The latest findings in gynaecological oncology were discussed at the 12th Charité-Mayo Conference. Prof. Sehouli shared his congress' highlights.

  • Heart failure remains the greatest challenge in cardiology

    How can the current "heart failure epidemic" be tackled? Prof. Dr Lars Maier provides an overview on the current state of affairs.

  • Precision medicine: The future of cardiology?

    Cardiology is facing technical and financial challenges. Demographic change also demands a new way of thinking about the specialty.

  • Gerontocardiology: Focusing on hypertensive elderly patients

    The current European guidelines (from 2018) recommend a mild reduction of blood pressure in older patients. But other studies advocate alternatives.

  • Does being a doctor make you happy? From work-life balance to burnout

    The medical profession is potentially one of the most risky professions. Dr. Ulrike Bossmann pleaded for physicians' self care despite pressure and stress.

  • SGLT2 inhibitors in HFpEF: good for heart and kidney

    It has not yet been conclusively clarified why SGLT2 inhibitors are associated with good outcomes in heart failure with pEF. The most relevant mechanisms of action were presented at the DGK 2023.

  • Update on comorbidities in heart failure: type 2 diabetes

    Heart failure in type 2 diabetics is associated with a significant increase in mortality. The most important comorbidities in heart failure were presented at the DGK 2023.

  • Update on mitral regurgitation: Which treatment is best for which disease entity?

    The concept of dysproportional mitral regurgitation makes it now possible to optimise therapy through meaningful patient characterisation.

  • The key issues of the 2022 ESC Guidelines

    The ESC published four new guidelines in 2022. We present the most important take-aways, as presented in the German Cardiology Congress (DGK) 2023.

  • Gene therapy for haemophilia: hopes for a bleeding-free life

    Haemophilia patients have relied on lifelong injections of the missing clotting factors. A single dose of a newly approved gen therapy could be sufficient.

  • Covid vaccination effective and safe in immunocompromised children

    Children with autoimmune diseases risk severe infections. The benefits of a COVID-19 vaccines for this group are still debated, but a recent study supports their use.

  • Psoriasis and the bones: arthritis is not the only problem

    In people with psoriatic arthritis (PsA), it is not only the joints that suffer: bone fractures and falls also occur more frequently, a recent study shows.

  • Errors in colonoscopy and how to avoid them

    Colonoscopy is complex, and endoscopy errors can occur. Targeted consideration of technical and non-technical skills can reduce avoidable errors and increase patient safety.

  • Amsler grid test: diagnostic accuracy assessed

    Ophthalmologists have relied on Amsler grid test accuracy regarding AMD diagnosis. But a new study is shaking up long-standing knowledge on this.

  • TACE: Transarterial chemoembolisation for hepatocellular carcinoma

    Local interventional procedures are being used in primary and secondary liver tumours. How does transarterial chemoembolisation work in HCC?

  • Women with non-Hodgkin's lymphoma benefit from chemotherapy in the afternoon

    Women suffering from diffuse large B-cell lymphoma (DLBCL) have better outcomes when chemotherapy is administered in the afternoon, according to a recent study.

  • COVID-19: drastic increase in incidence of severe vaccine reactions

    In the USA, the Florida Health Department published new data on reported severe reactions as of February 2023. The numbers are surprising.

  • Rheumatoid arthritis remission: real-world data

    A recent study has published real-world data on RA remission and investigated whether there are predictors that may make remission more likely.

  • Therapy-resistant liver metastases in colorectal carcinoma: DEBIRI can help

    Researchers investigated whether drug-eluting beads loaded with irinotecan (DEBIRI), and continuously release it, lead to improved therapy success.

  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |
  • 21 |
  • 22 |
  • 23 |
  • 24 |
  • 25 |
  • 26 |